Skip to content

Association Between Lactase Deficiency, and the Small Intestinal Microbiome in Adults.

Association Between Lactase Deficiency, Symptoms of Lactose Intolerance, and the Small Intestinal Microbiome in Adults

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03860051
Enrollment
37
Registered
2019-03-01
Start date
2018-11-21
Completion date
2023-06-30
Last updated
2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lactose Intolerance

Brief summary

The purpose of this study is to study the role of the enzyme (substance produced by the body that helps in a biochemical reaction like digestion in the body) responsible for digestion of lactose and the role of the gut bacteria (bacteria in the intestine) in producing symptoms of lactose intolerance.

Detailed description

The study involves 3 visits and will include 2 types of subjects - those who have the the diagnosis of lactose intolerance (subjects) and those who do not have lactose intolerance (controls). Visit 1: In total, it is estimated that the research participation will add about 1 hour to your planned procedure visit. At Visit 1 following will be done * Subjects will be asked to read and sign the informed consent after all the questions about the study have been answered. * General medical history will be taken including demographics, symptoms and history of illness, and medication review. * Vital signs (blood pressure, temperature, respiration, height, and weight) will be recorded. * Subjects will be asked to complete 2 questionnaires * Upper endoscopy will be done as part of routine clinical care * At the time of the endoscopy 4 extra biopsies (small piece of tissue) from the small intestines will be taken. The biopsies will be used for research to detect the bacteria and to measure the lactase enzyme. * Small sample of blood (10 mL) (2 teaspoons) will be taken for storage for possible future testing. This will be a one time draw only. * The research team may contact the subjects to arrange a Visit 2 if they are interested in proceeding with the next step in this research study. Visit 2: Visit 2 will take approximately 6 hours to complete. If the subject returns for Visit 2, they will do the following * They will return to the research office at Indiana University to participate in hydrogen breath test (test that uses the measurement of hydrogen in the breath to diagnose several conditions) to see how the body reacts to lactose. This involves drinking milk, then blowing into a bag so we can collect breath samples. Subjects will be asked to report any symptoms they might have during this time. This test will take approximately 6 hours. They will be instructed to eat a low-fiber meal the night before the test, and asked to fast for the 12 hours before the test. They can drink water during this time. * They will be also be asked to provide a stool sample for future analysis. Instructions for collection, storage and transportation of stool will be provided. They will be provided a kit for stool collection, storage and transportation. They will be asked to collect stool at home over the course of 2 days and store as per instructions. Stool will need to be refrigerated and brought back to the office on ice. Visit 3: Visit 3 will take approximately less than one hour to complete. For those who are interested in returning for Visit 3, * Subjects will be asked to return to the clinic with the stool samples. * They will complete the study at this time. Participants who complete Aim 1 and meet further eligibility criteria for Aim 2 may be contacted by research staff to return for Visit 2 (breath test). Those who are agreeable to participating and are scheduled for Visit 2 will be instructed to consume a low-fiber meal and fast for 12 hours prior to their breath test. We will contact the participant 24 to 48 hours prior to the test day as a reminder to consume a low fiber meal and fast for 12 hours.

Interventions

None listed

Sponsors

Indiana University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

Patient ages 18-75 presenting for upper gastrointestinal endoscopy for any indication except those outlined in the

Exclusion criteria

below at the IU GI Endoscopy Sites including: IU North Hospital, Glen Lehman Endoscopy Suite, Springmill/Beltway Surgery Center, IU Saxony, and Eskenazi Hospital will be eligible for participation. Participants should be willing and able to sign informed consent. Inclusion Criteria for Controls (Aim 1): Adult patients ages 18-75 years meeting basic eligibility criteria as listed above will be considered for inclusion. Participants should report no current or recent history of intolerance to and avoidance of dairy nor use of treatments and products for dairy intolerance. Inclusion Criteria for Patients with Self-Reported Lactose Intolerance (Aim 1): Adult patients ages 18-75 years meeting basic eligibility criteria as listed above will be considered for inclusion. Participants should report current or recent history of intolerance to and avoidance of dairy. Inclusion Criteria for Controls (Aim 2): All controls eligible for and completing Aim 1 will be considered eligible for inclusion. Participants should not meet any of the Aim 2

Design outcomes

Primary

MeasureTime frameDescription
Lactase activity1 dayLactase activity (µmol/min/g) will be assessed from small bowel biopsy specimens

Secondary

MeasureTime frameDescription
Symptom severity1 dayWe will assess symptom severity using the lactose assessment tool
Small intestinal mucosal microbiome1 dayThe small intestinal microbiome will be assessed by 16S allele PCR sequencing (16S) and Shotgun Metagenomic Sequencing (SGS)
Maldigestion status1 dayMaldigestion status will be assessed by hydrogen breath test
Fecal microbiome1 dayThe fecal microbiome will be assessed by 16S allele PCR sequencing (16S) and Shotgun Metagenomic Sequencing (SGS)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026